Merus’ Bispecific Antibody Therapy Shows Promising Early Results in Cancer Treatment

1. Merus, a clinical-stage oncology company, presented early data on its bispecific antibody therapy at the American Society of Clinical Oncology (ASCO) conference.
2. The data met investors' expectations, indicating potential efficacy in cancer treatment.
3. Bispecific antibodies are engineered to bind to two different targets, potentially increasing their therapeutic effect.
4. The specific type of cancer being treated and the exact nature of the results were not mentioned in the provided information.
5. The positive early results could potentially lead to further development and trials of this therapy.
6. The news was well-received by investors, suggesting confidence in the potential of this treatment approach.